Established in 2014, N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by
both increased incidences of the disease and development of new treatments.
Commercial strategy
N4 Pharma aims to develop and commercialise an in-house pipeline of differentiated RNA therapeutics. In the nearer term the Company will monetise the Nuvec® platform through commercial partnerships and licensing deals made possible by building a compelling data set demonstrating the key benefits of Nuvec® compared with established methods of nucleic acid delivery such as viral vectors and lipid nanoparticles. The aim is to establish Nuvec® as the industry standard for the delivery of nucleic acid therapies and drive widespread adoption of the technology.
Whilst focused on taking N4 101 into the clinic with an expected CTA/IND filing in 2027, N4 Pharma is using this programme to build out an extensive data set to demonstrate the key benefits of the Nuvec® platform which is essential to secure partnerships and licensing income in the nearer term.
If you would like further information or have any queries, please contact us.